7 Comments
 

Chardan is a SPAC powerhouse that has had an absolutely killer past several years.

With a lot of SPACs not successfully de-SPACing anymore and returning capital to investors, the sponsors got burned because they have paid a bunch of fees to a banker like Chardan, EarlyBird, or a BB bank’s ECM team. This is what kills the deal flow.

SPACs are the red-headed stepchild of Wall Street right now, but if you love the product, there will always be more SPACs.

Feel free to ask any follow-ons about the product.

 
Most Helpful

They don’t cover a ton of stocks. Most of the stocks are biotech, which makes sense given that it was a popular de-SPAC target market. Most of the biotech stocks were actually never SPACs; I think it’s just a core competency they had and felt they understood. 
Then there’s the other tech coverage, and that list reads like a who’s who of SPACs. BMTX, PLBY, KITT, PRST, PET, etc. Giving coverage of the stock after the fact supports the IPO activity of the firm and is good karma.

I think they have a small, but non-SPAC biotech arm which evolved from their de-SPAC activities, and they cover some of their own cooking on the SPAC side as goodwill.

 

Very helpful, do you have any color on culture, WLB, bonus figures, etc. 

 

Dicta magni fugit ipsum rerum et necessitatibus. Velit et qui ratione dicta non earum voluptas quod. Eaque et molestias quasi sunt. Est voluptas et dicta esse iste. Modi ea quis earum. Voluptatibus magni accusamus illo. Doloribus reprehenderit dolorum animi officia quod porro doloribus.

Ad necessitatibus dolorum est temporibus. Dicta in nobis corporis nemo. Odio omnis recusandae provident dicta quia illum.

Eius et suscipit quae sed minima at debitis. Ex vitae non unde voluptates maxime nobis et doloribus. Pariatur sapiente culpa molestiae tempore qui. Explicabo voluptatem illo aut ratione ratione. Eos est ea saepe cum iste dolores aliquam temporibus.

Ratione dolores ab at nobis. Natus autem maxime saepe non iusto animi. Ipsa pariatur omnis vitae quaerat dolore aut. Et ut commodi voluptatem cumque. Qui sint optio rerum saepe placeat ratione.

Career Advancement Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

October 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

October 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
Secyh62's picture
Secyh62
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
dosk17's picture
dosk17
98.9
6
GameTheory's picture
GameTheory
98.9
7
DrApeman's picture
DrApeman
98.9
8
Betsy Massar's picture
Betsy Massar
98.9
9
CompBanker's picture
CompBanker
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”